Abstract：
Distal ulcerative colitis (UC) is responsible for distressing symptoms and reduces quality of life (QoL). Oral and topical formulations of 5-amino-salicylic acid are the first line therapy for mild to moderate distal UC.
Our aim was to evaluate the impact of mesalazine treatment for mild to moderate ulcerative proctitis and proctosigmoiditis on patient QoL.
Ninety-three patients with mild to moderate ulcerative proctitis and proctosigmoiditis, initiating a treatment with Pentasa, were prospectively included. The primary endpoint was the change from baseline to W8 in patient health-related QoL (HRQoL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score.
More than 80% of patients were prescribed with a rectal formulation, either alone (47.9%) or with an oral formulation (35.1%), and 17.0% of patients were prescribed oral formulation alone. Mean SIBDQ score was improved at W8 in patients affected with mild and moderate disease ( P < 0.001 versus baseline in both groups, as well as in patients who achieved clinical remission ( P < 0.001). Patients who achieved clinical remission at W8 reached a mean change of +6.7 (±7.1), whereas those who did not achieve clinical remission had a mean change of +1.1 (±8.9). Seventy-five per cent of patients had an improvement of their disability index at W8. Fecal incontinence was also improved at W8.
HRQoL measuring with the SIBDQ is proportionally related to disease activity in patients with distal UC treated with mesalazine.
Our aim was to evaluate the impact of mesalazine treatment for mild to moderate ulcerative proctitis and proctosigmoiditis on patient QoL.
Ninety-three patients with mild to moderate ulcerative proctitis and proctosigmoiditis, initiating a treatment with Pentasa, were prospectively included. The primary endpoint was the change from baseline to W8 in patient health-related QoL (HRQoL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score.
More than 80% of patients were prescribed with a rectal formulation, either alone (47.9%) or with an oral formulation (35.1%), and 17.0% of patients were prescribed oral formulation alone. Mean SIBDQ score was improved at W8 in patients affected with mild and moderate disease ( P < 0.001 versus baseline in both groups, as well as in patients who achieved clinical remission ( P < 0.001). Patients who achieved clinical remission at W8 reached a mean change of +6.7 (±7.1), whereas those who did not achieve clinical remission had a mean change of +1.1 (±8.9). Seventy-five per cent of patients had an improvement of their disability index at W8. Fecal incontinence was also improved at W8.
HRQoL measuring with the SIBDQ is proportionally related to disease activity in patients with distal UC treated with mesalazine.
摘要：
背景：远端溃疡性结肠炎（UC）是造成痛苦症状并降低生活质量（QoL）的原因。5-氨基水杨酸的口服和局部制剂是轻度至中度远端UC的一线治疗。
目的：我们的目的是评估美沙拉嗪治疗轻中度溃疡性直肠炎和乙状结肠直肠对患者生活质量的影响。
方法：93例轻度至中度溃疡性直肠炎和直肠乙状结肠炎，开始用Pentasa治疗，被前瞻性地包括在内。主要终点是患者健康相关QoL（HRQoL）从基线到W8的变化，通过简短的炎症性肠病问卷（SIBDQ）总分测量。
结果：超过80％的患者使用直肠制剂，单独使用（47.9％）或口服制剂（35.1％），17.0%的患者仅口服处方。患有轻度和中度疾病的患者在W8时平均SIBDQ评分改善(两组与基线相比P<0.001,以及达到临床缓解的患者（P<0.001）。在W8达到临床缓解的患者平均变化为6.7（±7.1），而未达到临床缓解的患者的平均变化为+1.1(±8.9)。75%的患者在W8时残疾指数有所改善。在W8时大便失禁也得到改善。
结论：用SIBDQ测量的HRQoL与接受美沙拉嗪治疗的远端UC患者的疾病活动成比例相关。
目的：我们的目的是评估美沙拉嗪治疗轻中度溃疡性直肠炎和乙状结肠直肠对患者生活质量的影响。
方法：93例轻度至中度溃疡性直肠炎和直肠乙状结肠炎，开始用Pentasa治疗，被前瞻性地包括在内。主要终点是患者健康相关QoL（HRQoL）从基线到W8的变化，通过简短的炎症性肠病问卷（SIBDQ）总分测量。
结果：超过80％的患者使用直肠制剂，单独使用（47.9％）或口服制剂（35.1％），17.0%的患者仅口服处方。患有轻度和中度疾病的患者在W8时平均SIBDQ评分改善(两组与基线相比P<0.001,以及达到临床缓解的患者（P<0.001）。在W8达到临床缓解的患者平均变化为6.7（±7.1），而未达到临床缓解的患者的平均变化为+1.1(±8.9)。75%的患者在W8时残疾指数有所改善。在W8时大便失禁也得到改善。
结论：用SIBDQ测量的HRQoL与接受美沙拉嗪治疗的远端UC患者的疾病活动成比例相关。
